Clinical Trial Search

Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants

Primary: Number of Participants With Overall Response (OR) — 1 participants

Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years

Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs

Primary: Local Disease Control Assessed by Physical Examination — 0 Participants

Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants

Primary: Rate of Late Radiation Morbidity (≥ Grade 2 Lymphedema, Subcutaneous Fibrosis, or Joint Stiffness) at 2 Years From the Start of Radiotherapy as Measured by EORTC/RTOG…

Primary: Percentage of Patients With Progression-free Survival at 16 Weeks. — 36.4 Percentage of patients

Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)

Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…

Primary: Count of Patients With Dose Limiting Toxicity — 0 Participants

Primary: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) — 4; 1; 5; 0 participants

Primary: Cohorts 1, 3, 4, 5, 6 and 7: Objective Response Rate (ORR) — 9.4; 9.4; 0.0; 16.1 Percentage of participants

Primary: Late Radiation Toxicities at 2 Years From the Start of Radiation Treatment — 0 Participants

Primary: Rate of Complete Tumor Necrosis — 4 Participants

Primary: Number of Patients With Abdominal Recurrence or Death — 72; 73; 61; 60 Participants — p=0.955

Primary: Percentage of Participants With Progression-Free Survival (PFS) at 12 Weeks — 27.3; 12.5; 25.4; 50.0 percentage of participants

Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants

Primary: Number of Participants Who Experienced Serious Adverse Events and Adverse Events — 4; 5 Participants

Primary: Progression-free Survival — 83; 170 Days

Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months

Primary: Clinical Benefit Rate — 22 Participants

Primary: Disease Control Rate, Defined as the Number of Patients Who Achieved Complete Response, Partial Response or Stable Disease For a Period of More Than 4 Months. — 0…

Primary: Objective Response Rate, Evaluated According to the RECIST Criteria — 0 participants

Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants

Primary: Maximum Tolerated Dose (MTD) / Recommended Phase 2 Dosage for Each Cohort — 5; NA times per week of 125mg PO

Primary: Overall Objective Response — 5; 22; 8 participants

Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants

Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events

Primary: Tumor Best Response Rate — 0 Participants